CryoCell International Inc (CCEL)vsMerck & Company Inc (MRK)
CCEL
CryoCell International Inc
$3.42
-3.36%
HEALTHCARE · Cap: $23.36M
MRK
Merck & Company Inc
$123.54
-1.22%
HEALTHCARE · Cap: $308.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 210152% more annual revenue ($65.77B vs $31.28M). MRK leads profitability with a 13.6% profit margin vs -8.5%. CCEL appears more attractively valued with a PEG of 1.34. MRK earns a higher WallStSmart Score of 50/100 (D+).
CCEL
Hold39
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+34.8%
Fair Value
$5.12
Current Price
$3.42
$1.70 discount
Margin of Safety
-52.6%
Fair Value
$80.96
Current Price
$123.54
$42.58 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 129 in profit
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 3.6%
Earnings declined 80.5%
Distress zone — elevated risk
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CCEL
The strongest argument for CCEL centers on Return on Equity, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CCEL
The primary concerns for CCEL are Market Cap, Revenue Growth, EPS Growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
CCEL profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
CCEL carries more volatility with a beta of 0.57 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 39/100). CCEL offers better value entry with a 34.8% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CryoCell International Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?